NCT04695327已完成1 期
A Phase 1, Open-Label, Dose-escalation Clinical Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123) in Patients With Injectable Solid Tumors
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 32
- 试验地点
- 2
- 主要终点
- Number of Participants with abnormal laboratory values.
研究概览
简要总结
This is an open-label, phase 1, dose-escalation, multicenter trial evaluating the safety of oncolytic adenovirus TILT-123 as monotherapy in advanced solid tumor patients.
详细描述
This is an open-label, phase 1, dose-escalation trial evaluating the safety of TILT-123 as monotherapy in advanced solid tumor patients. TILT-123 is an oncolytic adenovirus coding for tumor necrosis factor alpha and interleukin 2. The trial includes 2 healthcare centers in Helsinki (Finland). Patients with different indications are expected to be treated in the trial.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65+ years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed and dated informed consent before any trial-related activities.
- •Male or female over 18 years of age
- •Pathologically confirmed refractory or recurrent injectable solid tumor, which cannot be treated with curative intent with available therapies.
- •Standard therapy has failed, it does not exist, is not available or is unlikely to result in meaningful clinical benefit (as assessed by the investigator). Other appropriate evidence-based therapies have failed or are contraindicated.
- •Multiple prior therapies (e.g. surgery, chemotherapy, checkpoint inhibitors, kinase inhibitors, biological therapies, hormonal therapies, radiation, etc) are allowed.
- •At least one tumor (>14 mm in diameter) must be available for injections and biopsies for correlative analyses. The disease burden must be measurable, but does not need to fulfil RECIST 1.
- •Adequate hepatic and renal functions as following:
- •Platelets > 75 000/mm3
- •Haemoglobin ≥ 100 g/L.
- •AST and ALT < 3 x ULN.
- •GFR >60 ml/min (Cockcroft-Gault formula).
- •Leukocytes (WBC) > 3,0
- •Bilirubin <1,5 x ULN
- •Men and women must be willing to use adequate forms of contraception from screening, during the trial, and for a minimum of 90 days after end of treatment, in accordance with the following:
- •Women of childbearing potential: Barrier contraceptive method (i.e. condom) must be used in addition to one of the following methods: Intrauterine device or hormonal contraception (oral contraceptive pills, implant, transdermal patches, vaginal ring or long-acting injections).
- •Women not of childbearing potential: Barrier contraceptive method (i.e. condom) must be used.
- •Men: Barrier contraceptive method (i.e. condom) must be used.
- •Demonstrated WHO/ECOG performance score of 0-1 at screening.
- •Life expectancy time longer than 3 months.
- •Capable of understanding and complying with parameters as outlined in the protocol.
排除标准
- •Use of immunosuppressive medications (corticosteroids or drugs used in treatment of autoimmune disease). Exempted are the following which can be allowed at screening and during the trial: a) replacement corticosteroids if e.g. the patient has adrenal insufficiency after prior immunotherapy b) inhaled and topical treatments c) up to 20 mg per day of prednisone/prednisolone.
- •Treated with any anti-cancer therapy within 30 days prior to the first virus injection. Anti-cancer therapy is defined as anti-cancer agents (e.g. cytotoxic chemotherapy, immunotherapy, signal-transduction inhibitors, etc) and investigational agents. An investigational agent is any drug or therapy that is currently not approved for use in humans. Continuation of hormonal therapy or use of bone modifying agents (eg. bisphosphonate or denosumab) is allowed if started at least 3 months before. Palliative radiation is not allowed within 14 days of the first virus injection (before or after), but it is allowed after day 15 during the trial treatment period, if deemed necessary by the investigator.
- •Uncontrolled cardiac or vascular diseases.
- •History of myocardial infarction or cerebral stroke within the previous 12 months before screening or is not sufficiently recovered from an older infarction or cerebral stroke.
- •History of severe hepatic dysfunction, hepatitis or HIV.
- •History of coagulation disorder.
- •Any other medical condition or laboratory abnormality that in the judgment of the principal investigator, may increase the risk associated with study participation or may interfere with interpretation of study results and /or otherwise make the patient inappropriate for entry into this trial.
- •Female patients who are pregnant, breastfeeding or intend to become pregnant.
- •Untreated brain metastases. Treated brain metastases which have not progressed in 3 months prior to screening are allowed.
- •Previously treated (within 5 years) with any oncolytic or replication deficient adenovirus.
- •Allergy to ingredients present in the investigational medicinal products (ingredients are listed in the protocol).
研究组 & 干预措施
Monotherapy
Experimental
Patients will receive multiple administrations of TILT-123.
Escalation to the next dose of TILT-123 level will occur when the safety data has been evaluated for all patients in the preceding dose level.
干预措施: TILT-123 (Biological)
结局指标
主要结局
Number of Participants with abnormal laboratory values.
时间窗: 85 days
Safety (II)
Number of Participants with vital sign abnormalities.
时间窗: 85 days
Safety (III)
Number of Participants with Adverse Events assessed by 12- lead electrocardiograms (ECGs)
时间窗: 85 days
Safety (IV)
Number of Participants with any (serious and non-serious) Adverse Events.
时间窗: 85 days
Safety (I)
次要结局
未报告次要终点
研究者
Claudia Kistler
Scientific
TILT Biotherapeutics Oy
研究点 (2)
Loading locations...
相似试验
终止
1 期
A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate CarcinomaMetastatic Castration-resistant Prostate CancerNCT04740034Amgen42
进行中（未招募）
1 期
A Study of TNB-383B in Participants With Relapsed or Refractory Multiple MyelomaMultiple MyelomaNCT03933735AbbVie220
已完成
1 期
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid TumorsAdvanced Solid TumorsUndifferentiated Pleomorphic SarcomaSquamous Cell Carcinoma of the Head and NeckCarcinoma of the BreastNCT02565758AbbVie85
终止
1 期
RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)Malignant Solid TumorMetastatic CancerAdvanced CancerNCT02801097EpicentRx, Inc.28
进行中（未招募）
1 期
Assessing the Safety and Efficacy of PLB1004 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)Non-Small-Cell Lung CancerNCT05347628Avistone Biotechnology Co., Ltd.91